BioWorld Asia

April 9, 2003

Serono Signs On Graffinity As Partner For Drug Development

Graffinity AG, a specialist in preclinical drug discovery, landed a commitment from Serono SA to help fill the development pipeline of Europe's largest biotechnology company. (BioWorld International) Read More

Epigenomics Raises EUR21M To Fund Work In DNA Methylation

Angiogenesis Study Encourages Prospects In Ischemia Treatment

GeneProt Slashes Staff, Cites Current Economic Environment

Ester Neuroscience Gets Good Results In Early Antisense Trial

Chiasma Gets First Biotech Investment From InnoMed

Galapagos Enters Collaboration In Nutraceuticals With Degussa

European Officials Craft Report On Embryonic Stem Cell Research

SR Pharma Taking Stock After Acquiring Rodaris, Joint Venture

EBML Targets Young Companies In Europe With New EUR25M Fund

Bioline Therapeutics Formed By Israeli Groups With $11M Funding

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 24, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 24, 2025.

Illustration of magnifying glass looking at cancer in the brain

Researchers discover how glioblastoma tumors dodge chemotherapy

BioWorld MedTech

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.